Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

CagriSema vs Dulaglutide

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Dulaglutide has stronger documented evidence (FDA-Approved) than CagriSema (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Dulaglutide is the safer pick. CagriSema may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

CagriSema

Phase 3

Dulaglutide

FDA-Approved

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

CagriSema Dulaglutide
Class Amylin + GLP-1 combination GLP-1 receptor agonist
Drug class Metabolic & Weight Metabolic & Weight
Mechanism Dual amylin + GLP-1 receptor agonism GLP-1 receptor agonist fused to human IgG4 Fc
Route SC injection SC injection
Half-life ~7 days ~5 days
Dosage (research) 2.4 mg / 2.4 mg SC weekly 0.75 mg SC weekly (Trulicity label starting dose, escalate stepwise to 1.5, 3.0, then label max 4.5 mg weekly for additional glycemic control per AWARD trials)
Evidence tier Phase 3 FDA-Approved
Research depth 113 indexed (PubMed 49 · CT 32 · EPMC 32) 311 indexed (PubMed 190 · CT 64 · EPMC 57)
Availability Investigational Prescription
Reported risks GI effects; Phase 3 REDEFINE mixed results Nausea; diarrhea; pancreatitis risk; thyroid C-cell tumor warning

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick CagriSema or Dulaglutide?

Dulaglutide has stronger documented evidence (FDA-Approved) than CagriSema (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Dulaglutide is the safer pick. CagriSema may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between CagriSema and Dulaglutide?

CagriSema is classed as Amylin + GLP-1 combination; Dulaglutide is classed as GLP-1 receptor agonist. Reported mechanism: CagriSema, Dual amylin + GLP-1 receptor agonism; Dulaglutide, GLP-1 receptor agonist fused to human IgG4 Fc. Reported half-life: CagriSema, ~7 days; Dulaglutide, ~5 days. Routes in published studies: CagriSema, SC injection; Dulaglutide, SC injection.

Which has stronger evidence, CagriSema or Dulaglutide?

Dulaglutide has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CagriSema is graded Phase 3, with 25 cited sources on its reference page and 113 indexed studies. Dulaglutide is graded FDA-Approved, with 41 cited sources on its reference page and 311 indexed studies.

Which is more accessible, CagriSema or Dulaglutide?

Dulaglutide is FDA-approved and CagriSema is not. Catalog status: CagriSema, Investigational; Dulaglutide, Prescription.

Are CagriSema and Dulaglutide ever combined?

CagriSema and Dulaglutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…